Shattering barriers toward clinically meaningful MSC therapies
The impact of pharmacologic agonists of ERR 80 and specific, partial, or dual agonists of PPAR and PPAR 81,82,83 , to together improve both SC- cell differentiation (through PPAR) and maturation/GSIS (through ERR) will be intriguing to assess for future translational benefit
doi:10.1111/ijcp.13409 Ritter
A multisociety delphi consensus statement on new fatty liver disease nomenclature
A 2.6% reduction in hip bone mineral density and a 2.1% reduction at the lumbar spine in 52 weeks (Hansen et al., 2024), combined with up to 10.9% lean mass loss over 72 weeks (Look et al., 2025), means that patients on GLP-1 therapy need a comprehensive musculoskeletal protection plan from day one
Heres our process for determining if BPC-157 is right for you: Initial Consultation The journey begins with a comprehensive consultation with one of our healthcare providers